The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy.

[1]  M. Penn,et al.  Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model , 2010, Thrombosis and Haemostasis.

[2]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[3]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[4]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Journal of the American College of Cardiology.

[5]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[6]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[7]  J. Björkman,et al.  Abstract 245: AZD6140 Inhibits Adenosine Uptake Into Erythrocytes and Enhances Coronary Blood Flow After Local Ischemia or Intracoronary Adenosine Infusion , 2007 .

[8]  Dan M. Roden,et al.  ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines , 2006 .

[9]  J. Headrick,et al.  Acute adenosinergic cardioprotection in ischemic-reperfused hearts. , 2003, American journal of physiology. Heart and circulatory physiology.

[10]  B. Lerman,et al.  Adenosine: Cardiac Electrophysiology , 1991, Pacing and clinical electrophysiology : PACE.

[11]  J. Fleiss,et al.  Effect of diltiazem on cardiac rate and rhythm after myocardial infarction. Multicenter Diltiazem Postinfarction Trial Investigators. , 1990, The American journal of cardiology.